Today, the first monoclonal antibodies, lecanemab and donanemab ... could have beneficial effects on cognition through ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

The data may help explain lecanemab’s therapeutic success, the authors suggested. They noted that for donanemab, additional studies of plaque binding will be needed to elucidate its mechanism of ...

In late 2022, the results of a groundbreaking stage-three trial for a ‘miracle’ new Alzheimer’s drug, lecanemab, were hailed as momentous. Finally, for the first time, a drug had slowed the ...

A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The preprint was posted on Research Square and had not been peer-reviewed ...

The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in research because they target a known cause of the disease, rather than just treating ...

Results from the open-label long-term extension study (OLE) following the core study of the lecanemab phase 3 Clarity AD study presented at AAIC in July, showed that the mean change from baseline ...

Lars Lannfelt will be one of the keynote speakers at the conference. In addition, BioArctic's partner Eisai present lecanemab data in two oral and one poster presentation at the meeting and three ...

New treatments for Alzheimer disease don’t reverse cognitive symptoms, but they do significantly slow progression. Evidence suggests that earlier treatment is most effective.

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...